SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Mirati Therapeutics, Inc. (NASDAQ: MRTX) for violations of federal securities laws.
On November 1, 2021, Mirati, in an SEC filing, disclosed that certain executives would no longer be serving in their positions. In the filing, the Company stated, “On October 28, 2021, it was determined that Daniel R. Faga would cease serving as the Executive Vice President, Chief Operating Officer and principal financial officer of Mirati Therapeutics, Inc. (the “Company”) and that Joseph Leveque would cease serving as the Company’s Executive Vice President and Chief Medical Officer, effective as of November 1, 2021.”
Following this news, Mirati stock was trading down over 15% mid-day on November 1, 2021.
If you have information that could assist in this investigation, including past employees and others, or if you are a Mirati shareholder and are interested in learning more about the investigation, please contact Jim Baker (firstname.lastname@example.org) at 619-814-4471. If emailing, please include a phone number.
Additionally, you can [Click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson Fistel, LLP
Jim Baker, 619-814-4471